Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

Presentation Icons

Live Streamed

On Demand

281 Views

A4. Treatment of antimicrobial resistant infections

Poster Session: Treatment of Antimicrobial Resistant Infections

(P-1492) Patient Characteristics Associated with Extended-Spectrum Beta-Lactamase-Producing Uropathogens: Pooled Results from Two Phase 3 Clinical Trials of Gepotidacin for the Treatment of Uncomplicated Urinary Tract Infection

Friday, October 18, 2024

12:15 PM – 1:30 PM US PT

Location: Halls JK

Presenting Author(s)

Jeremy Dennison, MD PhD

Director of Clinical Research
GSK, Brentford, UK
Brentford, England, United Kingdom

Amanda Sheets, PhD

Director, Clinical Development
GSK, Collegeville, PA, USA
Collegeville, Pennsylvania, United States
Caroline R. Perry, PhD (she/her/hers)

Sr Clinical Development Director
GSK, Collegeville, PA, USA
Collegeville, Pennsylvania, United States
FW

Florian Wagenlehner, MD

Justuf Liebeg University Diessen
Diessen, Hessen, Germany
Mark H. Wilcox, MD

PROFESSOR OF MEDICAL MICROBIOLOGY
LEEDS TEACHING HOSPITALS & UNIVERSITY OF LEEDS
LEEDS, England, United Kingdom
Nicole E. Scangarella-Oman, MS (she/her/hers)

Scientific Director
GlaxoSmithKline plc.
Collegeville, Pennsylvania, United States
DB

Deborah Butler, PharmD

VP & Head of Emerging Markets Regulatory Affairs at GSK
GSK
London, England, United Kingdom
JB

John Breton, MCM

GSK
Collegeville, Pennsylvania, United States
HM

Helen Millns, PhD

GSK, Stevenage, UK
Stevenage, England, United Kingdom
AM

Aruni Mulgirigama, MBBS

Global Medical Affairs Lead
GlaxoSmithKline plc.
Surrey, England, United Kingdom
MH

Matthew Helgeson, PharmD, MBA

GSK
Collegeville, Pennsylvania, United States
SJ

Salim Janmohamed, MD

GSK, Brentford, UK
Brentford, England, United Kingdom